Primary non-hodgkin's lymphoma of the bone: treatment and analysis of prognostic factors for Stage I and Stage II

Barbieri, Enza; Cammelli, S.; Mauro, F.; Perini, Francesco; Cazzola, Alberto; Neri, Stefano; Bunkheila, Feisal; Ferrari, Stefano; Brandoli, Vladimiro; Zinzani, Pier Luigi; Mercuri, Mario; Bacci, Gaetano

doi:10.1016/j.ijrobp.2003.11.020

Cited by 68 publications

(54 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In our series, 28.6 % of patients suffered a pathological fracture. The presence of a pathological fracture was found to be a negative prognostic factor by some authors [9,21], but this finding was not confirmed by other series [5,11]. Our data supported the latter finding.…”

Section: Discussioncontrasting

confidence: 61%

“…Persisting radiological abnormalities after treatment is a common finding in bone lymphomas and it does not prevent assessment of a remission state, which is evaluated upon the disappearance of local and systemic signs of lymphoma [5,11]. One patient achieved partial remission.…”

Section: Resultsmentioning

confidence: 99%

“…Little is reported about surgical procedures, even if surgery does, in some cases, become necessary for fractures or impending fractures. An incidence of orthopaedic surgical procedures other than biopsy, ranging from 13.8 % to 26 % [7][8][9][10] or even 47 % [5], is reported, but most papers either do not mention incidence or type of surgery [4,6,[11][12][13][14][15] or report incomplete data about the surgery performed [16,17]. Therefore, we decided to review our series in a single-centre, consecutive series of patients affected by primary bone lymphoma with the aim of: (1) evaluating incidence of surgery , (2) examining type of surgery and its combination with adjuvant treatment and (3) evaluating whether surgery should precede or follow radiotherapy and chemotherapy treatment.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Primary lymphoma of bone: outcome and role of surgery

Scoccianti

Rigacci

Puccini

et al. 2013

International Orthopaedics (SICOT)

View full text Add to dashboard Cite

Purpose Primary bone lymphoma is a rare disease. Little is reported about surgical procedures in these patients. We evaluated a single-centre consecutive series of 21 patients for results, prognostic factors and surgical treatment. Methods Patient ages ranged from 19 to 82 years. The most frequently affected site was the spine (six cases), followed by the ileum, femur and mandible (three cases each). Four patients were treated with chemotherapy and 17 with chemotherapy and radiation therapy. Six patients were affected by a pathological fracture. Surgery was performed in four patients (19 %), in two cases before chemotherapy, in one case during chemotherapy and in one case after chemotherapy and radiotherapy. Five patients died within the range of three to 36 months after diagnosis. Average follow-up of the remaining patients was 62.8 (19-145) months. Results Overall survival was 74.2 % at five years. The only positive prognostic factor was complete remission after chemotherapy. A trend for better survival was present for International Prognostic Index (IPI) score (P =0.051), under 40 years of age (P =0.10) and abnormal lactate dehydrogenase (LDH) values (P =0.10), but it did not reach statistical significance. Conclusions Surgical treatment should be aimed at restoring function and eliminating pain while minimising delays in the chemotherapy schedule. When feasible, postponing surgery until after chemotherapy is advisable.

show abstract

Section: Discussioncontrasting

confidence: 61%

Section: Resultsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Primary lymphoma of bone: outcome and role of surgery

Scoccianti

Rigacci

Puccini

et al. 2013

International Orthopaedics (SICOT)

View full text Add to dashboard Cite

show abstract

“…For instance, in the IELSG-14 study, the addition of radiotherapy following chemotherapy, or the use of larger radiation fields and doses, were not associated with an improved outcome in patients treated with chemoradiotherapy (9). Although previous studies have obtained contradicting results, chemoradiotherapy is likely to be superior to single modality therapy, which may be advantageous for localized unifocal bulky sites of disease, which allows a shorter chemotherapy course (1,30,35), or for multifocal disease in relapsing cases (36). Anthracycline-containing chemotherapy has become the standard therapy of DLBCL, while numerous studies have demonstrated increased long term remission rates with the incorporation of rituximab (33,(37)(38)(39)(40)(41)(42).…”

Section: Discussionmentioning

confidence: 99%

“…Finally, the transformation of treatment mode was inevitable, which depends on the stage. No conclusive view exists on the response of PBL to various radiotherapy doses, while the majority of studies used doses that are commonly used to treat NHL (35-45 Gy in 1.8-2 Gy fractions) (1,30,31). However, a randomized trial conducted in the British population revealed that radiotherapy at a dose of 30 Gy following chemotherapy was adequate for the treatment of NHL, including extra-nodal sites (60), while higher doses may be reserved for cases with a suboptimal response to chemotherapy.…”

Section: Discussionmentioning

confidence: 99%

Primary sternum diffuse large B-cell lymphoma: A case report and review of the literature

Tong

Zhang

et al. 2015

Oncology Letters

View full text Add to dashboard Cite

Abstract. Primary bone lymphoma (PBL) is a rare disease, accounting for >1% of all cases of malignant lymphoma. Diffuse large B-cell lymphoma (DLBCL) is the most common histological type of PBL. The present study reported the case of a 68-year-old male with primary bone DLBCL, originally occurred in the sternum, which is a rare form of presentation. Computed tomography (CT), magnetic resonance imaging and bone emission CT were performed, followed by immunohistochemical analysis of a biopsy specimen, and the results were used to establish the diagnosis. At the time of diagnosis, no osseous involvement was observed. The clinical, radiological and histological features of PBL can mimic other medical conditions, thereby making the diagnosis difficult, and frequently leading to delays in treatment. The present study investigated the clinical features, management and prognosis of PBL, and reviewed previous relevant cases.

show abstract

Primary extranodal diffuse large B‐cell lymphoma: Molecular features, treatment, and prognosis

Chen

et al. 2022

Aging and Cancer

View full text Add to dashboard Cite

Diffuse large B‐cell lymphoma (DLBCL) is the most common subtype of non‐Hodgkin's lymphoma and represents a heterogeneous entity. One‐third of DLBCL arises from extranodal organs and its prognosis often varies with regard to the sites involved. Molecular features are important to elucidate the differences in clinical features, predict the disease prognosis, and improve effective targeted therapeutic strategies. Extranodal DLBCLs originated from the breast, skin, uterus, immune‐privileged sites such as the central nervous system and testes, often show a high proportion of non‐germinal center B‐cell‐like (non‐GCB) phenotypes, with a high frequency of MYD88/CD79B mutations. In contrast, extranodal DLBCLs originated from the thyroid gland and stomach show a relatively low proportion of non‐GCB phenotype, with a considerably excellent prognosis. Immunochemotherapy with rituximab is the standard of care in both nodal and extranodal DLBCLs. However, approximately 40% of the patients experience treatment failure. It is critical to optimize the treatment strategy, including radiotherapy, autologous stem cell transplantation and targeted therapy according to the clinical characteristics and molecular heterogeneity. In this review, we present an overview of the key molecular pathways, prognosis assessment and innovative therapies in primary extranodal DLBCLs.

show abstract

Primary non-hodgkin's lymphoma of the bone: treatment and analysis of prognostic factors for Stage I and Stage II

Cited by 68 publications

References 20 publications

Primary lymphoma of bone: outcome and role of surgery

Primary lymphoma of bone: outcome and role of surgery

Primary sternum diffuse large B-cell lymphoma: A case report and review of the literature

Primary extranodal diffuse large B‐cell lymphoma: Molecular features, treatment, and prognosis

Contact Info

Product

Resources

About